Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Small Cell Lung Carcinoma 1Sarcoma 1Neurofibrosarcoma 1Neoplasms 1Lung Cancer - Malignant Pleural Mesothelioma 1Leukemia, Myeloid, Acute 1Leukemia 1Disorders of Sex Development 1

Interventions

selinexor 1pazopanib 1STA 9090 1Proton Therapy 1Paclitaxel 1Ifosfamide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Disorders of Sex Development × STA 9090 × Clear all
NCT02012192 2019-08-13

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Medical University Innsbruck

Phase 1/2 Terminated
133 enrolled 10 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Disorders of Sex Development

Data powered by HemOnc (CC BY 4.0) Colophon âš¡